Skip to main content

Merck KGaA targets higher growth

At its virtual capital markets day on 9 September, Merck KGaA announced that it aims to increase group sales by 6%/year to about €25 billion/year by 2025. To this end, investment, which will increase by 50% in the  years 2021-2025 compared to 2016-2020.

“We will continue to consistently and purposefully invest in areas that make us strong,” said CEO and executive board chair Belén Garijo (pictured). Merck will also seek targeted acquisitions, which are most likely to be small to medium-sized.

Ascensus buys Strem Chemicals

Ascensus has completed the acquisition of Strem Chemicals, bringing together two major suppliers of catalogue chemicals, mainly for life science, microelectronic and other speciality applications. Strem CEO Ephraim Honig will become chief science and innovation officer and will oversee the combined businesses’ R&D function.

Subscribe to life sciences